| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... Lancet, doi.org/10.1016/S0140-6736(18)30475-6, 2018 | 941 | 2018 |
| A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking CE Teunissen, A Petzold, JL Bennett, FS Berven, L Brundin, M Comabella, ... Neurology 73 (22), 1914, 2009 | 733 | 2009 |
| Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial GC Ebers, A Traboulsee, D Li, D Langdon, AT Reder, DS Goodin, ... Journal of Neurology, Neurosurgery & Psychiatry 81 (8), 907, 2010 | 164 | 2010 |
| The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS) T Bast, A Völp, C Wolf, D Rating Epilepsia 44 (2), 215-220, 2003 | 119 | 2003 |
| Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis DS Goodin, A Traboulsee, V Knappertz, AT Reder, D Li, D Langdon, ... Journal of Neurology, Neurosurgery & Psychiatry 83 (3), 282-287, 2012 | 115 | 2012 |
| Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies T Charlotte E, T Hayrettin, B Jeffrey L, B Frode S, B Lou, C Manuel, ... Multiple Sclerosis International 2011, 2011 | 89* | 2011 |
| Sulthiame as Monotherapy in Children with Benign Childhood Epilepsy with Centrotemporal Spikes: A 6‐Month Randomized, Double‐Blind, Placebo‐Controlled Study D Rating, C Wolf, T Bast Epilepsia 41 (10), 1284-1288, 2000 | 82 | 2000 |
| Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses RHB Benedict, D Tomic, BA Cree, R Fox, G Giovannoni, A Bar-Or, R Gold, ... Neurology, 2020 | 79 | 2020 |
| Blockade of chemokine signaling in patients with multiple sclerosis F Zipp, HP Hartung, J Hillert, S Schimrigk, C Trebst, M Stangel, ... Neurology 67 (10), 1880-1883, 2006 | 79 | 2006 |
| Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. A Randomized Clinical Trial. J Cohen, A Belova, K Selmaj, C Wolf, MP Sormani, J Oberyé, ... JAMA Neurol 72 (12), 1433-1441, 2015 | 77 | 2015 |
| Long-term follow-up of the original interferon-[beta] 1b trial in multiple sclerosis: Design and lessons from a 16-year observational study GC Ebers, AT Reder, A Traboulsee, D Li, D Langdon, DS Goodin, C Wolf, ... Clinical therapeutics 31 (8), 1724-1736, 2009 | 49 | 2009 |
| Efficacy and safety of siponimod in secondary progressive multiple sclerosis–Results of the placebo controlled, double-blind, Phase III EXPAND study L Kappos, A Bar-Or, B Cree, R Fox, G Giovannoni, R Gold, P Vermersch, ... 32nd Congress of the European Committee for Treatment and Research in …, 2016 | 47 | 2016 |
| Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents R Hagerman, S Jacquemont, E Berry-Kravis, V Des Portes, A Stanfield, ... Scientific reports 8 (1), 1-9, 2018 | 38 | 2018 |
| Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results K Selmaj, F Barkhof, AN Belova, C Wolf, ERW van den Tweel, JJL Oberyé, ... Multiple Sclerosis Journal 23 (14), 1909-1917, 2017 | 29 | 2017 |
| Treatment of restless legs syndrome with the dopamine agonist alpha‐dihydroergocryptine F Tergau, S Wischer, C Wolf, W Paulus Movement disorders 16 (4), 731-735, 2001 | 29 | 2001 |
| Reduction of voltage-operated sodium currents by the anticonvulsant drug sulthiame M Madeja, C Wolf, EJ Speckmann Brain research 900 (1), 88-94, 2001 | 24 | 2001 |
| The final results of the interferon beta-1b 16-year long-term follow-up study G Ebers, A Traboulsee, D Langdon, A Reder, C Miltenburger, C Wolf, ... | 20 | 2006 |
| Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis BAC Cree, B Magnusson, N Rouyrre, RJ Fox, G Giovannoni, P Vermersch, ... Multiple Sclerosis Journal, 1352458520971819, 2020 | 18 | 2020 |
| Replacement of oral valproate with intravenous valproate: a study on dose finding and bioavailability M Wangemann, C Wolf, A Retzow European Journal of CIinical Research 9, 209-215, 1997 | 16* | 1997 |
| Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis (P3. 2-051) R Benedict, R Fox, D Tomic, B Cree, P Vermersch, G Giovannoni, ... Neurology 92 (15 Supplement), P3. 2-051, 2019 | 12 | 2019 |
Robert J FoxMellen Center for Multiple Sclerosis, Cleveland ClinicVerified email at ccf.org
